Please login to the form below

Not currently logged in
Email:
Password:

Fishawack Group acquires Archimed Medical Communication

Pharmacovigilance specialists adds to group’s Swiss footprint

UK-headquartered Fishawack Group has acquired Swiss medical communications agency Archimed.

Based in Zofingen, Switzerland, Archimed offers clients medical writing, project management, and clinical research, consultancy and pharmacovigilance services.

The deal strengthens Fishawack's presence in Switzerland, adding to the group's Basel-based medical communications agency Phocus.

"We are very excited to have Archimed join the Group,” said Oliver Dennis, Fishawack CEO.

"In April, we linked up with a new investor, Growth Capital Partners, to allow us to continue to build the Fishawack Group, and this acquisition is the first step in our new phase of growth. We now have a global team of over 150 staff and the largest medical communications capability in Switzerland of any agency organisation."

Commenting on the acquisition, Françoise Rampelberg, general manager of Archimed, said: "I am very pleased that Archimed is becoming part of a larger group.

"There will be many opportunities for synergies across the group moving forward, and Fishawack and Archimed have very similar philosophies about quality, flexibility and client satisfaction.

"Our clients will benefit from access to further high-quality resources. Being part of a larger group will also offer more opportunities for the Archimed team."

12th June 2013

From: Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics